1 / 10

Bio-Society Issues and Related Processes

Bio-Society Issues and Related Processes. Andreas Seiter Novartis International. Purpose of this talk . Highlight core issues Reflect on stakeholder groups and diversity of views, based on “Access to healthcare” example

zarita
Download Presentation

Bio-Society Issues and Related Processes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bio-Society Issues and Related Processes Andreas Seiter Novartis International

  2. Purpose of this talk • Highlight core issues • Reflect on stakeholder groups and diversity of views, based on “Access to healthcare” example • Explain the need for a multi-stakeholder approach from an industry’s perspective • Initiate discussion on concrete steps towards potential msp’s

  3. Bio-Society Issues • Impact of genomics revolution on humanity and society at large • Ethical boundaries (e.g. embryonic stem cells, cloning of human beings, germ line therapy) • Novel risks (cross-species infections, new bio-warfare agents) • Access and benefit sharing (IP, costs, allocation of funding, equal access to treatment)

  4. The challenge of bio-innovation • All innovation has a tendency to be disruptive • Disruptive change creates fear: Loss of status, economic disadvantage, increasing external control of our live • Specific concerns in the Bio-Society debate: Potential for major impact on the fundamentals of human society • The goal of achieving equal access to live saving medicines for all becomes more difficult to achieve if such medicines become reality in increasing numbers - but at high costs

  5. Example: Access to novel drugs • Diversity and partial antagonism of pharmaceutical industry stakeholders • Customers (doctors and patients) • Shareholders (analysts, pension fund managers) • Employees • Payors (insurers, government agencies) • Politicians • Development agencies, NGO universe

  6. Elimination of risks is expensive higher < risk tolerance > lower

  7. Example: Access to novel drugs • Diversity and partial antagonism of pharmaceutical industry stakeholders • Customers (doctors and patients) • Shareholders (analysts, pension fund managers) • Employees • Payors (insurers, government agencies) • Politicians • Development agencies, NGO universe

  8. The innovation crisis • Old: Industry consolidation due to lack of innovation • New: Genomics revolution, North-South divide and aging society create a cocktail which threatens (remaining) consensus • A refined and more sustainable direction of global healthcare policies is in demand (priorities, funding) • The healthcare industry, used to portrait itself as a “philanthropic industry”, suddenly finds its business model under public attack

  9. Governance issues requiring MSP • Reducing the healthcare divide between the rich and the poor • Human rights versus luxury - where is the line? • Role of private (capital market funded) healthcare industry, sustainable business model • Balancing market forces with social and developmental goals • Measuring, monitoring, sharing “good practice” in pragmatic problem solving

  10. Who is in charge? • Who is in a position to set off a structured (global) debate? • How would it be linked into decision making processes? • Are there any “easy wins”? • How do current approaches to problem solving score against best practice? • Where are the relevant roadblocks and how can they be overcome?

More Related